Related by context. All words. (Click for frequent words.) 63 normal littermates 61 Untreated mice 61 biochemical relapse 60 advanced adenomas 60 mdx mice 60 infarcts 60 mutant worms 60 myocytes 59 HER2 positive tumors 59 MMSE scores 59 PSADT 59 achieved ACR# 59 immunized mice 59 complete cytogenetic response 58 Treated mice 58 CCyR 58 GBM tumors 58 ejection fractions 57 colorectal polyp 57 nondiabetic patients 57 receiving VICTRELIS 57 REYATAZ r arm 57 response CCyR 57 plus methotrexate 57 clodronate 57 troponin T 57 Median survival 57 hippocampal volumes 57 achieved CCyR 57 octreotide LAR 57 PASI scores 57 nontreated 57 pCR 57 timepoints 57 alanine aminotransferase ALT 56 metastatic lesions 56 interquartile range 56 estrogen receptor negative 56 extracapsular extension 56 mutated KRAS 56 paricalcitol 56 polypoid 56 Tumors shrank 56 hours postdose 56 % CI #.#-#.# [003] 56 preoperative chemotherapy 56 postdose 56 Marfan mice 56 placebo dexamethasone 56 colonic mucosa 56 infarct size 56 lopinavir r arm 56 baseline neutrophil counts 56 lung metastasis 56 lymphatic cancers 56 tumor shrinkage 56 glycated hemoglobin levels 56 hyperoxia 56 mg kg dose 56 conventional IMRT 55 lymph node involvement 55 P = .# 55 hemoglobin A1c levels 55 noninfected 55 #.#ng/ml 55 APOE ε4 55 CR nPR 55 lactate dehydrogenase 55 μmol L 55 preintervention 55 pamidronate 55 neostigmine 55 melanoma tumors 55 GO Y# 55 irradiated mice 55 EDSS scores 55 Breslow thickness 55 Thal Dex 55 atypical hyperplasia 55 ventricular enlargement 55 KRAS mutant tumors 55 NNRTI resistance 55 colorectal tumor 55 intermittent hypoxia 55 ALND 55 noncancerous prostate 55 isoproterenol 55 FLT3 ITD 55 MACCE 55 postnatally 55 RYGB surgery 55 lobular cancer 55 adriamycin 55 recurrent VTE 55 oral clodronate 55 relapsed MM 55 daunorubicin 55 lumbar spine BMD 55 timepoint 55 mitoxantrone 55 saline injections 55 colorectal adenoma 55 SUVmax 55 artery calcification 55 flutamide 54 placebo 54 benign nodules 54 chewed sugarless gum 54 mice 54 fumagillin nanoparticles 54 EDSS score 54 NRTI sparing 54 postintervention 54 splenectomized patients 54 atheroma volume 54 electrical cardioversion 54 Postoperatively 54 aminotransferase elevations greater 54 receiving ISENTRESS 54 inactive placebo 54 log# reduction 54 renal cell carcinomas 54 FOLFOX4 alone 54 FOLFOX4 54 serum concentrations 54 IFN alfa 54 liver metastasis 54 cisplatin resistant 54 liver metastases 54 distant metastases 54 develop premenopausal breast 54 doxorubicin cyclophosphamide 54 KRAS mutations occur 54 progression TTP 54 Doxil ® 54 #Gy 54 % CI #.#-#.# [007] 54 mammary tumors 54 SGS# 54 steroid dexamethasone 54 placebo p = 54 FluCAM arm 54 ductal breast cancer 54 progesterone receptor negative 54 binary restenosis 54 cortisol concentrations 54 colorectal neoplasms 53 advanced adenoma 53 eribulin 53 gross hematuria 53 Index CDAI score 53 concurrent chemoradiation 53 sulfasalazine 53 HBeAg negative patients 53 PaO 2 53 #mmHg [001] 53 oblimersen 53 p = #.# [002] 53 paclitaxel cisplatin 53 EBRT 53 mIU L 53 metastatic tumors 53 mcg albinterferon alfa 2b 53 antibiotic rifaximin 53 PRADAXA #mg 53 detectable BPA 53 solifenacin 53 locomotor activity 53 HBeAg seroconversion 53 HAART regimen 53 diabetic rats 53 antithymocyte globulin 53 HbA 1c levels 53 ethosuximide 53 achieved PASI 53 receptor blocker 53 placebo p 53 unsupplemented 53 Ishak fibrosis score 53 telomere lengths 53 patients evaluable 53 chlorambucil 53 fasting insulin 53 intraperitoneal injection 53 #OHD levels 53 mg simvastatin 53 Platelet counts 53 neutrophil counts 53 #mg/day [002] 53 ductal cancer 53 cabazitaxel 53 mcg dose 53 neoplastic cells 53 idraparinux 53 baseline LDH 53 leucopenia 53 hepatic insulin sensitivity 53 aminotransferases 53 bezafibrate 53 nadroparin 53 precancerous polyp 53 postoperatively 53 serum testosterone levels 53 neurodevelopmental impairment 53 CK MB 53 rCBF 53 lymphocytosis 53 synovial fibroblasts 53 5-FU/LV 53 μg mL 53 QTcF 53 airway hyper responsiveness 53 oxycodone CR 53 mg/m2 dose 53 imipramine 53 systolic function 53 μg ml 53 locoregional recurrence 53 glomerular filtration 53 neurologic outcomes 53 μg doses 53 neuritic 53 nM 53 bleomycin 53 esophageal tumors 53 ertapenem 53 underwent resection 53 uM 53 lumbar spine bone 53 p = ns 53 homozygotes 53 brain lesions 53 mammary gland tumors 53 hippocampi 52 carotid IMT 52 dapagliflozin plus 52 neurocognitive function 52 plasma glucose 52 poorer prognosis 52 amoxicillin clavulanate 52 hippocampal cells 52 intravenous diuretics 52 atypical neuroleptics 52 experimentally induced 52 sentinel nodes 52 fibrous tangles 52 nmol l 52 nonmetastatic 52 hypophosphatemia 52 PSA nadir 52 desvenlafaxine succinate 52 shorter telomeres 52 NPY expression 52 daily subcutaneous injections 52 mononuclear cells 52 mg QD 52 noncarriers 52 squamous cell carcinoma SCC 52 ethambutol 52 leukocyte counts 52 gastric pH 52 neurofibromas 52 polyp recurrence 52 corticosterone levels 52 nonobese 52 differentiated thyroid 52 Triglyceride levels 52 CC genotype 52 MCF7 cells 52 radiographic progression 52 mammary tumor formation 52 serologically active patients 52 hippocampal volume 52 Cortisol levels 52 maximal aerobic capacity 52 locoregional disease 52 HBeAg positive patients 52 MADRS score 52 radiochemotherapy 52 adjuvant cisplatin 52 LAB GHRH 52 metastatic lung cancer 52 8mg/kg 52 nodal metastasis 52 nondiabetic 52 ACR# responses 52 perioperatively 52 fraction LVEF 52 biopsied breast 52 serum testosterone 52 #mg/m# [002] 52 adefovir 52 blastic phase 52 seropositivity 52 baseline A1C 52 dalteparin 52 CDAI score 52 Lumbar spine 52 micrometastases 52 cytoreduction 52 colorectal carcinomas 52 micromolar 52 GIST tumors 52 heterozygotes 52 AVODART 52 dopamine neurons 52 wildtype 52 alteplase 52 hormone receptor negative 52 CD4 + cells 52 posttreatment 52 nondepressed 52 Rectal cancer 52 SCIg 52 hyperglycaemic 52 plasma HCV RNA 52 microgram dose 52 serum clusterin levels 52 pulmonary dysfunction 52 fasting plasma glucose FPG 52 MMSE score 52 QRS duration 52 white matter hyperintensities 52 etanercept 52 GBA mutations 52 streptokinase 52 normoxic 52 detectable HCV RNA 52 diastolic function 52 leptin deficient mice 52 Hair follicles 52 highest tertile 52 Irs2 52 submaximal exercise 52 anaplastic 52 undetectable PSA 52 left ventricular systolic 52 cytoreductive surgery 52 FluCAM 52 pg ml 52 mitoxantrone plus 52 stress hormone corticosterone 52 care regimens CCR 52 uninfected mice 52 littermates 52 HIV uninfected 52 folic acid takers 52 nicardipine 52 TT genotype 52 antibody titers 52 Leydig cell 52 hippocampal neurons 52 reinfarction 52 HLA DRB1 SE 52 nmol liter 52 cortical thickness 52 metastatic melanomas 52 CIN3 52 operable breast cancer 52 tertile 52 immunocompromised mice 52 interferon alfa 52 B. fragilis 52 transaminase elevations 52 verum acupuncture 52 colorectal adenomas 52 lymphocyte count 52 postop 52 chemotherapy gemcitabine 52 axillary node dissection 52 brachial artery flow 52 refractory ischemia 52 posttransplant 52 systolic dysfunction 52 pg mL 51 endometrial thickness 51 neurologic complications 51 deficient mice 51 seropositive patients 51 HER2 expression 51 nonmelanoma skin cancers 51 Flu Cy 51 molindone 51 p = NS 51 zolmitriptan 51 colorectal tumors 51 atherosclerotic lesions 51 locoregional 51 cranial irradiation 51 pT3 51 urinary excretion 51 tumor nodules 51 metabolic parameters 51 bilateral oophorectomy 51 #mg doses [002] 51 vestibular schwannomas 51 partial remissions 51 Immune responses 51 NPH insulin 51 SIDS infants 51 pulmonary metastases 51 median PFS 51 indinavir 51 placebo dummy pill 51 polypoid lesions 51 femoral shaft fracture 51 serum homocysteine 51 dexrazoxane 51 6 OHDA 51 mg TID 51 mycophenolate mofetil 51 T2 lesions 51 Scale EDSS 51 -#.# mg dL [001] 51 ug ml 51 BMPR2 51 tolterodine ER 51 ropivacaine 51 VO2 peak 51 IELT 51 GSTT1 51 alanine aminotransferase 51 anticholinergic drugs 51 HER2 positive cancers 51 squamous histology 51 PBMCs 51 pmol L 51 HIV RNA 51 AdPLA 51 urate levels 51 hsCRP levels 51 Psoriasis Area 51 BEACOPP 51 glioblastoma tumors 51 cisplatin chemotherapy 51 Mitomycin C 51 distant metastasis 51 serum BDNF 51 prostate glands 51 Mice lacking 51 conduction velocity 51 adenotonsillectomy 51 endostatin 51 HNSCC 51 ovariectomized 51 anemia hemoglobin 51 ADPKD 51 definite stent thrombosis 51 serum creatinine levels 51 neurologic progression 51 FOLFIRINOX 51 GISTs 51 peptide YY 51 unformulated vaccine 51 severe neutropenia 51 peritoneal carcinomatosis 51 intramuscularly 51 racemic albuterol 51 biochemical recurrence 51 hypovolemic 51 methotrexate monotherapy 51 EGFRIs 51 virologic breakthrough 51 pancreatic adenocarcinoma 51 RAS blockers 51 β blockers 51 ginkgo biloba extract 51 diastolic hypertension 51 rimonabant #mg 51 tipranavir r 51 invasive carcinomas 51 occluded catheters 51 Crohn Disease Activity 51 oral prednisone 51 AGTR1 51 MPTP 51 VT VF 51 umol L 51 MBq 51 Akt phosphorylation 51 μg dL 51 transferrin saturation 51 ketorolac 51 mg ustekinumab 51 postoperative complications 51 ADAS cog 51 diabetic mice 51 eotaxin 51 mIU ml 51 MGUS 51 HU# [002] 51 neoadjuvant radiation 51 prostates removed 51 experienced virologic failure 51 overt nephropathy 51 parous women 51 VaD 51 tamoxifen Nolvadex ® 51 #mg dose [001] 51 Folfox 51 viral titers 51 hepatic enzymes 51 hypoxia induced 51 mmHg systolic 51 D2 receptors 51 mRNA expression 51 breast carcinomas 51 undetectable HBV DNA 51 hemorrhagic complications 51 unconjugated 51 pentoxifylline 51 osteosarcomas 51 BALB c mice 51 fluorouracil 51 androgen deprivation 51 preeclamptic 50 sumatriptan naproxen sodium 50 basal cell cancers 50 oophorectomy 50 intensive statin therapy 50 tenecteplase 50 euthyroid 50 HbA1C levels 50 Baseline characteristics 50 estim ated fewer 50 corticosterone 50 carcinoid 50 dobutamine 50 mediastinal lymph nodes 50 CIMZIA TM 50 evaluable subjects 50 triacylglycerol concentrations 50 intestinal polyps 50 Viread Emtriva Sustiva 50 NYHA class 50 mutated K ras 50 PKC beta 50 dummy capsules 50 PEG Intron 50 cell carcinomas 50 malignant melanomas 50 Engerix B 50 PD# [005] 50 baseline HbA1c 50 waist circumferences 50 inflammatory lesions 50 KRAS mutations 50 EGFR mutation positive 50 infarcted myocardium 50 stage IIIb IV 50 transplanted islets 50 mutant mice 50 uterine tumors 50 cancerous nodes 50 recurrent venous thromboembolism 50 NIHSS 50 coronary calcification 50 A1c levels 50 CYPHER Stent 50 lymphopenia 50 metabolically healthy 50 #mg BID [001] 50 leukocyte count 50 pancreatic resection 50 ejaculatory function 50 premenopause 50 AGILECT R 50 adjunctive placebo 50 colorectal carcinoma 50 adalimumab 50 mcg BID 50 Leydig cells 50 ANAVEX #-# [001] 50 brain shrinkage 50 bowel polyps 50 peritoneal cancer 50 rebleeding 50 WOMAC pain 50 TRUS biopsy 50 contractile function 50 RLS sufferers 50 neoadjuvant therapy 50 peginterferon alfa 2a 50 TET2 50 5FU 50 endometrial hyperplasia 50 plus dexamethasone 50 include ketoconazole acetaminophen 50 dexamethasone Decadron 50 ALT elevation 50 fructose diet 50 elevated ALT 50 deep venous thromboses 50 Homocysteine levels 50 resected pancreatic cancer 50 normothermic 50 tumor regression 50 ximelagatran 50 insulin lispro 50 inhaled fluticasone 50 calcitriol 50 thyrotropin levels 50 REMICADE monotherapy 50 #.#/#.# mmHg [001] 50 interferon ribavirin 50 regrew 50 mcg mL 50 mm Hg diastolic 50 Median PFS 50 intravenous bisphosphonates 50 basal cell skin 50 Tumours 50 cultured neurons 50 albumin excretion rate 50 CDAI 50 hematologic toxicity 50 C diff infections 50 distal colon cancer 50 tumor recurrence 50 moderately emetogenic 50 SETDB1 50 serum IGF 50 % Confidence Interval 50 detecting precancerous 50 deferoxamine 50 PsA 50 serum HCV RNA 50 univariate analysis 50 Adjuvant chemotherapy 50 hypofractionated radiation 50 liver histology 50 ovulatory cycles 50 normal karyotype 50 virologic response 50 APTIVUS r 50 pilocytic astrocytoma 50 -#.# log# copies mL 50 normotensive 50 mg dose 50 glyburide 50 downregulated 50 seminomas 50 aprepitant 50 T2 lesion volume 50 ß amyloid 50 DAS# remission 50 HBV DNA 50 incontinence episodes 50 MELD scores 50 transplanted kidneys 50 thyroglobulin 50 seroprotection 50 Operative mortality 50 anticholinergics 50 saline placebo 50 mmHg diastolic 50 virologic failure 50 Complication rates 50 invasive lobular 50 Endothelial function 50 intra articular injection 50 severe exacerbations 50 nonexposed 50 nonresponders 50 virological response 50 serum urate 50 IGFBP 3 50 preoperative PSA 50 thymosin 50 cervical lymph nodes 50 engraftment 50 stage IIIB IV 50 zoledronate 50 weekly intravenous infusions 50 male Sprague Dawley 50 inert placebo 50 decitabine 50 comparator arm 50 xenograft tumors 50 HbA1c levels 50 mL/min/#.# m 2 50 median survivals 50 ionotropic 50 diuretic chlorthalidone 50 underwent liver transplantation 50 subcutaneous enoxaparin 50 enamel defects 50 OGTT 50 HBeAg 50 receiving prophylactic anticoagulation 50 TAXUS Express Stent 50 noncancerous cells 50 graft dysfunction 50 serous ovarian cancer 50 subclinical hyperthyroidism 50 GSTM1 50 ADAS Cog 50 mcg QD 50 multivariate adjustment 50 slow metabolizers 50 inhaled budesonide 50 seminal vesicle invasion 50 dopamine neuron 50 ob ob mice 50 malignant neoplasm 50 inhibited tumor 50 heavily pretreated patients 50 dummy pill 50 Peg IFN 50 seroprotective 50 ACTEMRA TM 50 bronchopulmonary dysplasia 50 #mg/kg [002] 50 warfarin erythromycin 50 Camptosar ® 50 mm Hg systolic 50 cardiac dysfunction 49 nmol L. 49 oral squamous cell 49 oxycodone IR 49 hip BMD 49 Legg Calvé Perthes disease 49 androgen suppression 49 smallest tummies 49 serum phosphorus levels 49 silibinin 49 serum phosphate levels 49 metastatic bladder 49 salivary cortisol 49 abdominal subcutaneous fat 49 coronary artery calcification 49 myeloablative 49 arterial stiffening 49 underarm lymph nodes 49 db db mice 49 lispro 49 amisulpride 49 beta blocker therapy 49 non mutated KRAS 49 pulmonary exacerbation 49 adenoma recurrence 49 Biopsies 49 estramustine 49 recurrent wheezing 49 urinary albumin 49 recurrent myocardial infarction 49 asymptomatic PAD 49 progestin pills 49 HBeAg positive 49 fluvastatin 49 p# activation 49 CK # plasma concentrations 49 tolvaptan 49 recurrent GBM 49 dacarbazine chemotherapy 49 Kaplan Meier estimate 49 sulphonylureas 49 endometrial cells 49 creatinine ratio 49 nonsmall cell lung cancer 49 oral Hycamtin 49 ruptured aneurysms 49 rHuEPO 49 mg/m2 IV 49 reintervention 49 nifedipine 49 radioiodine therapy 49 LVEF 49 cilostazol 49 TOF PET 49 postoperative chemotherapy 49 Sprague Dawley rats 49 non progressors 49 rFSH 49 postprandial insulin 49 Viread Emtriva 49 subarachnoid hemorrhages 49 asymptomatic carotid stenosis 49 lobule 49 micronuclei 49 pegylated interferon alpha 49 lamivudine monotherapy 49 sensory neuropathy 49 intravenous cyclophosphamide 49 APOE e4 49 hydroxyvitamin D levels 49 hepatocellular carcinomas 49 Target Lesion Revascularization TLR 49 kainate 49 alveolar epithelial cells 49 intracranial atherosclerosis 49 sustained virologic response 49 perioperative complications 49 DSAEK 49 bladder cancers 49 malignant lymphoma 49 taxotere 49 PTHrP 49 metastatic tumor 49 neuroblastoma cells 49 sentinel lymph node biopsy 49 methacholine challenge 49 mutant flies 49 relapsers 49 androgen ablation 49 mesalamine granules 49 CI -#.# 49 normal ULN 49 nadolol 49 acetaminophen codeine 49 symptom exacerbation 49 CLL cells 49 fibrinolysis 49 immunoreactivity 49 aspartate aminotransferase AST 49 nonfasting triglyceride levels 49 platelet aggregation 49 fluticasone 49 CD8 cells 49 colon tumors 49 hyaluronic acid fillers 49 mineral density 49 immuno suppression 49 plasma leptin 49 FOLFIRI alone 49 aspartate aminotransferase 49 rosuvastatin #mg 49 melanocyte stimulating hormone 49 TNFa 49 imatinib 49 benign noncancerous 49 lymphovascular invasion 49 peginterferon 49 GLUT1 49 antiandrogen 49 leuprolide 49 leukopenia 49 neoplasias 49 intact parathyroid hormone 49 intraductal 49 MAS XR 49 NP CRNs 49 IL 1beta 49 painkiller naproxen 49 tibolone 49 platelet stickiness 49 specific antigen PSA 49 flow mediated dilation 49 pulmonary metastasis 49 PREZISTA r arm 49 debulking surgery 49 CD# upregulation 49 RGT arm 49 p = .# [001] 49 NNT = 49 urothelial cancer 49 OGG1 49 FOLPI 49 Premenopausal women 49 premenopausal breast cancer 49 receiving APTIVUS r 49 p = .# [002] 49 oral antidiabetes 49 p = #.# [004] 49 Barrett mucosa 49 GnRH agonist 49 severe hepatic dysfunction 49 painful erections 49 seminoma 49 flavanol cocoa 49 lymph node metastasis 49 crossclamp 49 plasma glucose levels 49 rat pups 49 obstructive coronary artery 49 μg L 49 myocardial reperfusion 49 attain statistical significance 49 gadobutrol 49 NYHA functional class 49 estrogen progestin combination 49 Circulating tumor cells 49 got Abbott MitraClip 49 receptor inhibitor 49 hepatoma 49 S#K# 49 impaired endothelial 49 copies mL 49 Chlamydia infection 49 anaplastic astrocytomas 49 EGFR mutant 49 epithelial tissues 49 CMV antibodies 49 pegIFN 49 neuroblastoma tumors 49 P. acnes 49 Severity Index PASI 49 neuromuscular junctions 49 basal cell nevus syndrome 49 hydroxychloroquine 49 neuroD2 49 gemcitabine carboplatin 49 serum parathyroid hormone 49 medically inoperable 49 sFlt 1 49 salivary flow 49 pyridostigmine 49 shortened telomeres 49 tumors 49 MIF gene 49 μg kg 49 PCa 49 plasma concentrations 49 sticky clumps 49 spirometric 49 clinically evaluable patients 49 FASPS 49 linezolid 49 interferon alfa 2b 49 evaluable 49 low dose Iluvien 49 GH secretion 49 antihypertensive therapy 49 elevated triglyceride levels 49 hyperplastic 49 atazanavir ritonavir 49 prospectively stratified 49 insulin secreting cells 49 GSTM1 gene 49 undergone splenectomy 49 VEGF expression 49 WNV encephalitis 49 circulating lymphocytes 49 trophoblast cells 49 microbleeds 49 MetS 49 graft occlusion 49 skeletal myoblasts 49 hormone receptor status 49 Insulin sensitivity 49 albumin excretion 49 sinus rhythm 49 nmol 49 glioblastomas 49 drank pomegranate juice 49 certolizumab 49 lactulose 49 symptomatic intracerebral hemorrhage 49 Neural stem cells 49 arteriolar 49 allogeneic HSCT 49 p = #.# [003] 49 DRG neurons 49 ipsilateral stroke 49 clinically meaningful improvement 49 cytogenetic response 49 LV ejection fraction 49 hMG 49 axillary dissection 49 motoneurons 49 4mg/kg 49 ‰ ¥ 49 nonischemic cardiomyopathy 49 platelet reactivity 49 XL# administered orally 49 telomeres shorten 49 pulmonary arterial 49 castrate resistant 49 antiandrogens 49 HDL LDL ratio 49 adenomatous polyp 49 rizatriptan 49 revascularized 49 ng dL 49 mitochondrial biogenesis 49 skeletal muscle tissue 49 cisplatin 48 oxyntomodulin 48 metastatic gastric 48 removed laparoscopically 48 sUA 48 plus MTX 48 Wistar rats 48 azacitidine 48 SHBG levels 48 exudative AMD 48 symptom onset 48 antiestrogen therapy 48 lung adenocarcinomas 48 Valcyte tablets 48 lowest tertile 48 UPDRS motor 48 Aß# 48 breastfed infants 48 histological subtype 48 nonsignificant difference 48 R0 resection 48 MS relapses 48 urate lowering therapy